BIOA BioAge Labs
- 22.190
- +1.570+7.61%
- 21.090
- -1.100-4.96%
BioAge Labs News
Morgan Stanley Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $40
Morgan Stanley Keeps Their Buy Rating on BioAge Labs, Inc. (BIOA)
BioAge Labs | 10-Q: Quarterly report
Express News | Bioage Labs Inc Qtrly Shr Loss $6.70
Express News | Bioage Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
BrainTransporter Dramatically Improves Antibody Delivery to the Brain
Invitation to Presentation of BioArctic's Third Quarter Report for July - September 2024 on November 14 at 9.30 A.m. CET
Express News | CORRECTION: Bioage Labs Ticker Is "BIOA"
Express News | BioAge Labs To Present New Preclinical Data For Lead Product Candidate Azelapragor At ObesityWeek 2024
BioAge Labs to Present at Jefferies London Healthcare Conference
Citi Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $45
Goldman Sachs, Morgan Stanley Bullish on BioAge, Cite Lilly Relationship
Wall Street Analysts Initiate Coverage of BioAge Labs
Citi Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $45
Bioage Labs Analyst Ratings
Jefferies Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $42
Morgan Stanley Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $40
BioAge Labs Initiated With an Overweight at Morgan Stanley
BioAge Labs, Inc.: Promising Developments and Strategic Partnerships Lead to Buy Rating
BioAge Labs Initiated With a Buy at Jefferies
Analysis
Price Target
No Data
No Data
